The neoadjuvant regimen of antracycline/taxane chemotherapy plus trastuzumab/pertuzumab is the gold standard treatment for high-risk HER2-positive early BC [[10], [11], [12]] according to the evidence-based clinical research. Here, ERBB2 is linked to breast cancer.